bioAffinity Technologies, Inc. (BIAF) Spending and interest coverage
- R&D / revenue · 12 months: Value 23.99%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 15.80%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 23.99% | Research and development expense / revenue. Period ending 2026-06-30. $1.42M ÷ $5.90M × 100 ≈ 23.99% |
| Stock-based compensation / revenue · 12 months | 15.80% | Share-based compensation / revenue. Period ending 2026-06-30. $932.53K ÷ $5.90M × 100 ≈ 15.80% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 1.42M USD | Research and Development Expense |
| Revenue | 5.90M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 932.53K USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -12.38M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.42M | $5.90M | $932.53K | $-12.38M | (m) | 23.99% | 15.80% | (m) | (m) |
| 2026-03-31 | $1.37M | $5.66M | $359.20K | $-11.56M | (m) | 24.13% | 6.35% | (m) | (m) |
| 2025-12-31 | $1.38M | $6.16M | $671.47K | $-10.57M | (m) | 22.45% | 10.90% | (m) | (m) |
| 2025-09-30 | $1.40M | $6.78M | $839.44K | $-10.38M | (m) | 20.66% | 12.39% | (m) | (m) |
| 2025-06-30 | $1.34M | $7.68M | $958.00K | $-10.06M | (m) | 17.50% | 12.47% | (m) | (m) |
| 2025-03-31 | $1.43M | $8.81M | $1.03M | $-9.64M | (m) | 16.29% | 11.72% | (m) | (m) |
| 2024-12-31 | $1.46M | $9.36M | $989.68K | $-8.95M | (m) | 15.61% | 10.57% | (m) | (m) |
| 2024-09-30 | $1.50M | $9.37M | $990.10K | $-8.35M | (m) | 16.05% | 10.57% | (m) | (m) |
| 2024-06-30 | $1.56M | $7.32M | $990.86K | $-8.67M | (m) | 21.31% | 13.54% | (m) | (m) |
| 2024-03-31 | $1.49M | $4.94M | $874.92K | $-8.36M | $59.02K | 30.21% | 17.72% | -141.66× | Reported |
| 2023-12-31 | $1.47M | $2.53M | $748.82K | $-7.97M | $37.13K | 57.96% | 29.57% | -214.77× | Reported |
| 2023-09-30 | $1.23M | $321.49K | $551.16K | $-7.25M | $101.09K | 382.13% | 171.44% | -71.76× | Reported |
| 2023-06-30 | $1.32M | $24.16K | $443.73K | $-5.94M | $988.81K | 5461.38% | 1836.93% | -6.00× | Reported |
| 2023-03-31 | $1.23M | (m) | $300.16K | $-4.84M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $1.14M | $4.80K | $248.59K | $-4.01M | $2.53M | 23792.98% | 5175.77% | -1.58× | Reported |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $1.01M | (m) | $43.01K | $-2.21M | $1.00M | (m) | (m) | -2.20× | Reported |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |